Practical considerations reveal liposomal bupivacaine improves analgesia after surgery, suggesting a non-opioid pain management strategy.
Abstract » Opioid-related dependence remains a major concern following surgery in the United States, driving increased interest in non-opioid, multimodal pain control strategies within orthopaedic surgery. » Liposomal bupivacaine is an extended-release anesthetic approved for specific nerve blocks and offers the potential to prolong analgesia without the need for post-operative catheters. » Liposomal bupivacaine is currently approved for use in interscalene brachial plexus blocks, sciatic nerve blocks in the popliteal fossa, and adductor canal blocks. » Despite mixed clinical trial results compared to unencapsulated bupivacaine, liposomal formulations may provide clinical and economic advantages in selected orthopaedic settings.
No takes yet. Share an insight, caveat, or question.
Goltz et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: